vudalimab

Phase 2Monoclonal antibody

XXencor, Inc.

vudalimab is one of 63 biologic programs targeting Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Thyroid CancerActive, not recruiting

Prostate CancerPhase 1

Active, not recruiting

Thyroid CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

Mekinist

Novartis

Preclinical

3 3

Trexall

Alnylam Pharmaceuticals

vudalimab

2 5

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 6

Prednisone/prednisolone

Roche

Preclinical

3 7

Triptorelin Pamoate

Ipsen

Preclinical

2 8

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—9

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Xylocaine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Thyroid Cancer

NCT05453799

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Completed·XXencor, Inc.·Phase 2·NCT05005728·72 enrolled

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Terminated·EEmory University·Phase 1·NCT05733351·4 enrolled

Malignancies1 trial

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Active, not recruiting·XXencor, Inc.·Phase 2·NCT05032040·170 enrolled

Thyroid Cancer1 trial

Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer

Active, not recruiting·NNorthwestern University·Phase 2·NCT05453799·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for vudalimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — vudalimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for vudalimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xencor, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: XXencor, Inc.

vudalimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Prostate Cancer2 trials

Malignancies1 trial

Thyroid Cancer1 trial

References

Drug Info

Quick Facts

Related News